Aarhus University Hospital

Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)

Retrieved on: 
Mardi, décembre 5, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Principal, Safety, ANCA, Cirrhosis, Disease, Nephritis, RPGN, Clinical trial, Patient, Dialysis, CLDN1, Pharmacokinetics, University of Cambridge, Immunoglobulin A, Kidney, Diabetes, Trial of the century, Lupus, Aarhus University Hospital, Vasculitis, Pharmaceutical industry

The randomized, double-blind, placebo-controlled Phase 2 study ( NCT06047171 ) of lixudebart evaluates the drug’s safety, tolerability, pharmacokinetics, and how well it protects against the loss of kidney function.

Key Points: 
  • The randomized, double-blind, placebo-controlled Phase 2 study ( NCT06047171 ) of lixudebart evaluates the drug’s safety, tolerability, pharmacokinetics, and how well it protects against the loss of kidney function.
  • The study plans to recruit patients with Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis with Rapidly Progressive Glomerulonephritis (RPGN).
  • This disease typically causes a rapid and dramatic loss of kidney function and can result in kidney loss with patients requiring dialysis or a transplant.
  • It is the second clinical trial investigating lixudebart in patients after the initiation of a clinical study in advanced liver fibrosis patients earlier this year,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis.

MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADV

Retrieved on: 
Mercredi, octobre 11, 2023
Inflammation, Aarhus University Hospital, DLQI, Safety, Hurley, Hidradenitis suppurativa, Patient, Therapy, HSP90, CMO, MC2, Clinical trial, News, HS, Pharmaceutical industry, Medical imaging

The single center, Phase 2a, clinical trial conducted at Aarhus University Hospital, Denmark evaluated the efficacy and safety of MC2-32 in patients with moderate to severe (Hurley stage 2 or 3) HS.

Key Points: 
  • The single center, Phase 2a, clinical trial conducted at Aarhus University Hospital, Denmark evaluated the efficacy and safety of MC2-32 in patients with moderate to severe (Hurley stage 2 or 3) HS.
  • 15 patients were recruited for the study and randomized 2:1, to 16 weeks oral treatment with 250 mg MC2-32 once daily or placebo.
  • The study was a Phase 2a proof-of-concept study and not designed to obtain statistical significance.
  • Joining our strong portfolio of immunology and inflammation treatments in development and on the market, MC2 Therapeutics is on its way to becoming an emerging force in the field.”

NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2

Retrieved on: 
Mardi, juin 20, 2023
Ohio State University, Nextgen, University, Observational study, University of Missouri, EMG, Aarhus University Hospital, Department of Neurology, Xuanwu hospital, Facial muscles, CMT, PNS, Neuromuscular junction, Patient, Fatigue, NMJ, Ohio State University Wexner Medical Center, Neurology, Study, Disease, Safety, Pharmaceutical industry, Medical imaging, Medical device, Establishment

Results from the study establish, for the first time, neuromuscular junction (NMJ) transmission deficit as a new disease characteristic in patients with Charcot-Marie-Tooth (CMT) type 1 and 2.

Key Points: 
  • Results from the study establish, for the first time, neuromuscular junction (NMJ) transmission deficit as a new disease characteristic in patients with Charcot-Marie-Tooth (CMT) type 1 and 2.
  • The level of NMJ transmission deficit in patients with CMT was associated with disease severity assessed through a range of clinical measurements of muscle strength and function.
  • The international study was led by Dr. Henning Andersen, Aarhus University Hospital, and Dr. William David Arnold, NextGen Precision Health, University of Missouri*.
  • NMD Pharma is developing NMD670, a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel.

NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2

Retrieved on: 
Mardi, juin 20, 2023
Ohio State University, Nextgen, University, Observational study, University of Missouri, EMG, Aarhus University Hospital, Department of Neurology, Xuanwu hospital, Facial muscles, CMT, PNS, Neuromuscular junction, Patient, Fatigue, NMJ, Ohio State University Wexner Medical Center, Neurology, Study, Disease, Safety, Pharmaceutical industry, Medical imaging, Medical device, Establishment

Results from the study establish, for the first time, neuromuscular junction (NMJ) transmission deficit as a new disease characteristic in patients with Charcot-Marie-Tooth (CMT) type 1 and 2.

Key Points: 
  • Results from the study establish, for the first time, neuromuscular junction (NMJ) transmission deficit as a new disease characteristic in patients with Charcot-Marie-Tooth (CMT) type 1 and 2.
  • The level of NMJ transmission deficit in patients with CMT was associated with disease severity assessed through a range of clinical measurements of muscle strength and function.
  • The international study was led by Dr. Henning Andersen, Aarhus University Hospital, and Dr. William David Arnold, NextGen Precision Health, University of Missouri*.
  • NMD Pharma is developing NMD670, a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel.

Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer

Retrieved on: 
Mardi, mars 14, 2023
Bladder cancer, University, Arunachal University of Studies, Congress, Knowledge, EAU, BLC, White Light, Tumor microenvironment, Recurrence, Risk, Name, European Association of Urology, Sorbonne University, HAL, Patient, WLC, ClinicalTrials.gov, Calendar, Division, Health, APHP, TURBT, Aarhus University Hospital, Cystoscopy, Urology

OSLO, Norway, March 14, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the European Association of Urology congress (EAU) in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy (BLC®) in Bladder Cancer management.

Key Points: 
  • OSLO, Norway, March 14, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the European Association of Urology congress (EAU) in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy (BLC®) in Bladder Cancer management.
  • This year's event was held on March 10 -13, 2023 and attracted urologists from all over the world.
  • In addition to an active presence & support for the event, Photocure will also be making bladder cancer session highlights available post event by means of video interviews with the presenters of these sessions.
  • "These new study results continue to emphasize the importance of performing a thorough TURBT using Blue Light Cystoscopy in the treatment of bladder cancer, and also demonstrate the strong interest from the scientific community to investigate Hexvix®/Cysview's potential immunologic effects in bladder cancer management.

Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer

Retrieved on: 
Mardi, mars 14, 2023
Bladder cancer, University, Arunachal University of Studies, Congress, Knowledge, EAU, BLC, White Light, Tumor microenvironment, Recurrence, Risk, Name, European Association of Urology, Sorbonne University, HAL, Patient, WLC, ClinicalTrials.gov, Calendar, Division, Health, APHP, TURBT, Aarhus University Hospital, Cystoscopy, Urology

OSLO, Norway, March 14, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the European Association of Urology congress (EAU) in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy (BLC®) in Bladder Cancer management.

Key Points: 
  • OSLO, Norway, March 14, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the European Association of Urology congress (EAU) in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy (BLC®) in Bladder Cancer management.
  • This year's event was held on March 10 -13, 2023 and attracted urologists from all over the world.
  • In addition to an active presence & support for the event, Photocure will also be making bladder cancer session highlights available post event by means of video interviews with the presenters of these sessions.
  • "These new study results continue to emphasize the importance of performing a thorough TURBT using Blue Light Cystoscopy in the treatment of bladder cancer, and also demonstrate the strong interest from the scientific community to investigate Hexvix®/Cysview's potential immunologic effects in bladder cancer management.

Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

Retrieved on: 
Jeudi, juin 9, 2022
National Center for Advancing Translational Sciences, Aarhus University Hospital, Aarhus University, Degenerative disease, Autoimmune disease, CMO, Research, Autoimmunity, European Society of Radiology, CEO, Coronavirus Scientific Advisory Board (Turkey), IPC, MC2, All India Mahila Congress, Itchy, Maintenance, Multimedia, University, I&I, Therapy, Topical medication, Patient, Psoriasis, DDS, ESDR, MD, Family, CKD, Urea, Uremic pruritus, Skin, View, Dermatology, Hotel manager, Technology, Pharmaceutical industry, EU

COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.

Key Points: 
  • COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.
  • "Lars Iversen brings substantial experience and an extensive international network in the field of dermatology to the company," said Jesper J. Lange, CEO of MC2 Therapeutics.
  • Professor Lars Iversen has been a member of the International Psoriasis Council (IPC) board of directors since 2017.
  • Lars Iversen (Professor, MD, DMSc) is chair professor in dermatology at University of Aarhus since 2012.

Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

Retrieved on: 
Jeudi, juin 9, 2022
National Center for Spinal Disorders, Aarhus University Hospital, Aarhus University, Degenerative disease, Autoimmune disease, CMO, Research, Autoimmunity, European Society of Radiology, CEO, Coronavirus Scientific Advisory Board (Turkey), IPC, MC2, All India Mahila Congress, Itchy, Maintenance, University, I&I, Therapy, Topical medication, Patient, Psoriasis, DDS, ESDR, MD, Family, CKD, Urea, Uremic pruritus, Skin, Dermatology, Hotel manager, Technology, Pharmaceutical industry, EU

COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.

Key Points: 
  • COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.
  • "Lars Iversen brings substantial experience and an extensive international network in the field of dermatology to the company," said Jesper J. Lange, CEO of MC2 Therapeutics.
  • Professor Lars Iversen has been a member of the International Psoriasis Council (IPC) board of directors since 2017.
  • Lars Iversen (Professor, MD, DMSc) is chair professor in dermatology at University of Aarhus since 2012.

Magneto Thrombectomy Solutions Announces Successful First-in-Human Results for Treatment of Pulmonary Embolism (PE)

Retrieved on: 
Mardi, mai 10, 2022
Transfer, Artery, Solution, Thrombectomy, Company, Stroke, Safety, Data, Leg, Patient, Pulmonary embolism, Thrombus, BGU, Aarhus University Hospital, FIH, Ben-Gurion University of the Negev, Breathe Me, BIOMED, PE, Prognosis, Efficiency, PERT, Embolism, Technology, CEO, Association of British HealthTech Industries, Medical imaging, Pharmaceutical industry, Computer data storage, Birth control, Magneto, Incentive

OR YEHUDA, Israel, May 10, 2022 /PRNewswire/ -- Magneto Thrombectomy Solutions (Magneto), a medical devices company developing innovative thrombectomy solutions for the treatment of ischemic stroke and pulmonary embolism, presented today successful first-in-human (FIH) results showing safety and feasibility of the eTrieve™ system, a novel catheter based on electric fields for removing blood clots, in patients with acute pulmonary embolism (PE). The data, presented today at Biomed Israel 2022, the premier international Life Science and HealthTech conference in Israel (May 10-12, Tel Aviv), showed a significant reduction in RV/LV ratio and alleviation of PE associated symptoms.

Key Points: 
  • "We are very pleased with our FIH results, which confirm the safety and efficiency of our innovative technology, as previously demonstrated in preclinical studies," said Benny Dilmoney, CEO of Magneto.
  • "Our novel catheter is a groundbreaking solution that can transform treatment of conditions caused by blood clots, such as pulmonary embolism.
  • PE is a rapidly growing market enhanced by the Pulmonary Embolism Response Team (PERT) approach for PE management.
  • Magneto Thrombectomy Solutions is developing innovative thrombectomy solutions for the treatment of ischemic strokes and pulmonary embolisms.

ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology

Retrieved on: 
Mercredi, avril 6, 2022
IST, CAC All-Tradable, CAC, Asparaginase, European Medicines Agency, Medicine, ISIN, Technology, Asparagine, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GMP, Pancreatic cancer, 150, Wiley, CAC Mid 60, Hypersensitivity, Metabolism, Allergy, Principal investigator, Organic acid, Growth, Survival, Nordic Society for Middle Eastern Studies, ALL, FDA, Patient, Company, British Journal of Haematology, Bone marrow, Paper, Associate, Cancer, Food, Acute lymphoblastic leukemia, Safety, Aarhus University Hospital, PHASE 2, Blood, Pharmaceutical industry, Medical imaging, Red blood cell, Euronext

The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological profile of eryaspase in ALL patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy.

Key Points: 
  • The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological profile of eryaspase in ALL patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy.
  • Eryaspase demonstrated sustained asparaginase enzyme activity above the threshold of >100 U/L at trough levels 14 days after first infusion in 92.5% of patients.
  • The Principal Investigator, Dr. Birgitte Klug Albertsen, Associate Professor at Aarhus University Hospital, Denmark, commented, "I am grateful that the editors of the British Journal of Haematology selected our study for publication.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.